Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Hellmann

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Does CSF pleocytosis have a predictive value for disease course in MS?Itay Lotan, Felix Benninger, Rom Mendel, et al.
Journal of Neuroimmunology|September 30, 2018
Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody diseaseItay Lotan, Mark A Hellmann, Felix Benninger, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 28, 2016
Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual OutcomeJudith Brody, Mark A Hellmann, Romain Marignier, et al.
Journal of Neurology|July 9, 2025
Familial myasthenia gravis: characterization of an Israeli cohort and systematic review of the literatureMark A Hellmann, Israel Steiner, Maor Mermelstein, et al.
Acta Neurologica Scandinavica|March 8, 2020
Incidence of AChR Ab-positive myasthenia gravis in Israel: A population-based studyItay Lotan, Felix Benninger, Mark A Hellmann, et al.
Neuromuscular Disorders : NMD|March 1, 2022
Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravisItay Lotan, Mark A Hellmann, Yitzhak Friedman, et al.
European Journal of Neurology|July 21, 2021
Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in IsraelItay Lotan, Adi Wilf-Yarkoni, Yitzhak Friedman, et al.
European Journal of Neurology|March 19, 2026
Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control StudyTasneem Kab, Keshet Pardo, Mark A Hellmann, et al.
Frontiers in Immunology|April 18, 2022
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine DosesRon Milo, Elsebeth Staun-Ram, Dimitrios Karussis, et al.
The Israel Medical Association Journal : IMAJ|July 31, 2024
Applicability of the New Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Diagnostic Criteria in an Israeli CohortAviv Fineberg, Itay Lotan, Omer Bialer, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Does CSF pleocytosis have a predictive value for disease course in MS?Itay Lotan, Felix Benninger, Rom Mendel, et al.
Journal of Neuroimmunology|September 30, 2018
Recurrent optic neuritis - Different patterns in multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody diseaseItay Lotan, Mark A Hellmann, Felix Benninger, et al.
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|June 28, 2016
Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual OutcomeJudith Brody, Mark A Hellmann, Romain Marignier, et al.
Journal of Neurology|July 9, 2025
Familial myasthenia gravis: characterization of an Israeli cohort and systematic review of the literatureMark A Hellmann, Israel Steiner, Maor Mermelstein, et al.
Acta Neurologica Scandinavica|March 8, 2020
Incidence of AChR Ab-positive myasthenia gravis in Israel: A population-based studyItay Lotan, Felix Benninger, Mark A Hellmann, et al.
Neuromuscular Disorders : NMD|March 1, 2022
Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravisItay Lotan, Mark A Hellmann, Yitzhak Friedman, et al.
European Journal of Neurology|July 21, 2021
Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in IsraelItay Lotan, Adi Wilf-Yarkoni, Yitzhak Friedman, et al.
European Journal of Neurology|March 19, 2026
Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control StudyTasneem Kab, Keshet Pardo, Mark A Hellmann, et al.
Frontiers in Immunology|April 18, 2022
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine DosesRon Milo, Elsebeth Staun-Ram, Dimitrios Karussis, et al.
The Israel Medical Association Journal : IMAJ|July 31, 2024
Applicability of the New Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Diagnostic Criteria in an Israeli CohortAviv Fineberg, Itay Lotan, Omer Bialer, et al.
Pageof 4